Healthcare Sector
Market Tracker
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
Expires | Type | Strike | OI | Change | Percent |
---|---|---|---|---|---|
06/20/2025 | PUT | $150.00 | 3,588 | +1,000 | +38.64% |
08/15/2025 | PUT | $160.00 | 392 | +326 | +493.94% |
06/20/2025 | CALL | $230.00 | 1,150 | +321 | +38.72% |
06/20/2025 | PUT | $105.00 | 346 | +309 | +835.14% |
06/20/2025 | PUT | $120.00 | 807 | +270 | +50.28% |
01/17/2025 | CALL | $182.50 | 824 | +258 | +45.58% |
06/20/2025 | PUT | $160.00 | 1,158 | -33 | -2.77% |
01/31/2025 | PUT | $175.00 | 1,651 | -35 | -2.08% |
03/21/2025 | PUT | $175.00 | 1,465 | -36 | -2.40% |
01/31/2025 | CALL | $180.00 | 245 | -45 | -15.52% |
01/17/2025 | PUT | $165.00 | 3,248 | -81 | -2.43% |
03/21/2025 | PUT | $170.00 | 3,081 | -118 | -3.69% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
Name | Pct Held | Shares | Total |
---|---|---|---|
Vanguard Total Stock Market Index Fund | 3.05% | 53.76M | 7.26B |
Vanguard 500 Index Fund | 2.32% | 40.88M | 5.52B |
Fidelity 500 Index Fund | 1.10% | 19.39M | 2.62B |
SPDR S&P 500 ETF Trust | 1.09% | 19.15M | 2.58B |
American Mutual Fund Inc | 1.00% | 17.6M | 2.38B |
iShares Core S&P 500 ETF | 0.89% | 15.78M | 2.13B |
Vanguard Index-Value Index Fund | 0.87% | 15.28M | 2.06B |
Capital Income Builder, Inc. | 0.84% | 14.87M | 2.01B |
Select Sector SPDR Fund-Health Care | 0.81% | 14.36M | 1.94B |
Washington Mutual Investors Fund | 0.75% | 13.22M | 1.78B |
NUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ Countries
01/09 11:53 am
GlobeNewswire Inc.
Read moreAlzheimer's Disease Diagnostics Research Report 2024-2034: Global Market to Reach $27.87 Billion - Focus on Cost-Effective Alzheimer's Diagnostics Gaining Momentum
01/09 11:48 am
GlobeNewswire Inc.
Read moreImmunotoxins Market Trends and Regional Business Opportunities, 2024-2034: Diphtheria Toxin-Based Immunotoxins Lead Revenue, Pseudomonas Exotoxins Show Rapid Growth Potential
01/09 05:52 am
GlobeNewswire Inc.
Read moreThe Smartest Dividend Stocks to Buy With $500 Right Now
01/06 06:45 am
The Motley Fool
Read more2 No-Brainer Dividend Stocks to Buy With $250 in 2025
01/06 05:17 am
The Motley Fool
Read moreTime to Dump or Double Up on SCHD?
01/04 09:35 am
The Motley Fool
Read more3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
01/04 06:19 am
The Motley Fool
Read moreBioconjugation Market Global Forecast to 2029 with Danaher, Lonza, Thermo Fisher Scientific, Merck, AbbVie, WuXi Biologics, and Sartorius Leading
01/02 08:52 am
GlobeNewswire Inc.
Read moreThe Smartest Dividend Stocks to Buy With $1,000 Right Now
12/26 06:35 am
The Motley Fool
Read morePharmaceuticals & Medicine Manufacturing Market Set to Surge at 8.9% CAGR, to Reach US$ 2,516.46 Million by 2034 | Fact.MR Report
12/24 07:30 am
GlobeNewswire Inc.
Read moreIs AbbVie Stock a Buy?
12/23 09:30 am
The Motley Fool
Read more2 Excellent Dividend Stocks to Buy on the Dip
12/23 05:32 am
The Motley Fool
Read more2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
12/22 07:50 am
The Motley Fool
Read more3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
12/21 07:48 am
The Motley Fool
Read moreIs AbbVie Ready for a Bullish Turn?
12/17 03:15 am
Investing.com
Read moreWant Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
12/15 06:35 am
The Motley Fool
Read moreTwo Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
12/09 01:00 pm
GlobeNewswire Inc.
Read moreAbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study
12/09 12:16 pm
Benzinga
Read moreCancer Monoclonal Antibodies Market to Grow at a 18.4% CAGR through 2031 | SkyQuest Technology
12/09 08:10 am
Benzinga
Read moreFive-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
12/08 01:30 pm
GlobeNewswire Inc.
Read moreInvestigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
12/07 08:12 pm
GlobeNewswire Inc.
Read more3 High-Dividend, High-Growth Stocks to Gift Your Portfolio This Holiday Season
12/04 10:30 am
Investing.com
Read more3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer
12/03 05:24 am
The Motley Fool
Read more3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
12/01 06:52 am
The Motley Fool
Read moreWant Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
11/30 06:41 am
The Motley Fool
Read moreProton Pump Inhibitors Market to Surpass Valuation of USD 7.35 Billion by 2031 | SkyQuest Technology
11/25 05:51 am
GlobeNewswire Inc.
Read moreThe Stock Market Is Soaring but These 2 Stocks Are Still Dirt Cheap Buys
11/23 10:17 am
The Motley Fool
Read more3 Dividend Stocks That Are Screaming Buys in November
11/23 08:20 am
The Motley Fool
Read moreProtein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3% | Transparency Market Research, Inc.
11/15 07:00 am
GlobeNewswire Inc.
Read moreGot $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
11/15 06:50 am
The Motley Fool
Read more2 Dividend Stocks to Buy Hand Over Fist in November
11/14 11:15 am
The Motley Fool
Read moreAbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
11/12 02:52 pm
Benzinga
Read moreAbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
11/11 01:51 pm
Benzinga
Read moreNeuroscience Market Projected to Reach USD 50.2 Billion by 2032, Growing at a 4.0% CAGR – S&S Insider
11/11 12:45 pm
GlobeNewswire Inc.
Read moreAbbVie Stock Slips As $9 Billion Schizophrenia Studies Flunk, Bristol-Myers Stock Surges
11/11 11:27 am
Benzinga
Read more3 Spectacular High-Yield Dividend Stocks to Buy in November
11/10 10:30 am
The Motley Fool
Read moreMy Favorite Dividend King to Buy in November
11/09 06:48 am
The Motley Fool
Read moreBristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
11/08 03:35 pm
Benzinga
Read moreThe Physician-Patient Alliance for Health & Safety Expands Board of Advisors with Five Healthcare Industry Leaders, Enhancing Commitment to Patient Safety and Innovation
11/06 11:00 am
GlobeNewswire Inc.
Read more5 Dividend Stocks to Double Up on Right Now -- Plus Some Dividend ETFs
10/31 05:30 am
The Motley Fool
Read moreMedical Spa Market to hit USD 55.3 billion by 2032, says Global Market Insights Inc.
10/29 04:30 am
GlobeNewswire Inc.
Read more2023 Vision Health Report: Post Pandemic Recovery-Challenges Remain
10/28 10:56 am
GlobeNewswire Inc.
Read more3 Dividend Growth Stocks You Can Buy and Hold Forever
10/26 07:30 am
The Motley Fool
Read moreBeat the Nasdaq With This Cash-Gushing Dividend Stock
10/23 06:50 am
The Motley Fool
Read more3 Growth Stocks That Could Be Bargain Buys Right Now
10/18 05:20 am
The Motley Fool
Read moreFDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year
10/17 11:31 am
Benzinga
Read moreBiopharmaceuticals Contract Manufacturing Industry Research 2024-2030: Biopharma Giants Increasingly Outsource to Streamline Drug Developments
10/14 10:58 am
GlobeNewswire Inc.
Read moreChemotherapy Drugs Market Report 2024: Essential Growth Dynamics and Advancements to 2030
10/14 10:54 am
GlobeNewswire Inc.
Read more2 Magnificent Dividend Stocks to Buy and Hold Forever
10/14 09:45 am
The Motley Fool
Read more